Capital Fund Management (CFM)
NBIX icon

Capital Fund Management (CFM)’s Neurocrine Biosciences NBIX Stock Holding History

Capital Fund Management (CFM)’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.5M Sell
98,117
-51,514
-34% -$7.64M 0.07% 389
2026
Q1 		$19.7M Buy
149,631
+69,506
+87% +$9.22M 0.09% 314
2025
Q4 		$11.4M Sell
80,125
-43,579
-35% -$6.31M 0.03% 755
2025
Q3 		$17.4M Sell
123,704
-79,924
-39% -$10.8M 0.05% 572
2025
Q2 		$25.6M Buy
203,628
+27,987
+16% +$3.21M 0.07% 385
2025
Q1 		$19.4M Buy
175,641
+71,117
+68% +$9.01M 0.06% 453
2024
Q4 		$14.3M Sell
104,524
-7,048
-6% -$872K 0.04% 601
2024
Q3 		$12.9M Buy
111,572
+54,621
+96% +$7.49M 0.04% 622
2024
Q2 		$7.84M Buy
+56,951
New +$7.81M 0.02% 777
2021
Q2 		– Sell
-60,266
Closed -$5.86M – 1576
2021
Q1 		$5.86M Buy
60,266
+40,409
+204% +$4.24M 0.06% 366
2020
Q4 		$1.9M Sell
19,857
-2,810
-12% -$271K 0.02% 795
2020
Q3 		$2.18M Buy
22,667
+3,329
+17% +$385K 0.03% 614
2020
Q2 		$2.36M Sell
19,338
-4,305
-18% -$476K 0.04% 453
2020
Q1 		$2.05M Buy
+23,643
New +$2.31M 0.03% 520
2019
Q3 		– Sell
-6,932
Closed -$585K – 1805
2019
Q2 		$585K Buy
6,932
+3,612
+109% +$297K 0.01% 1166
2019
Q1 		$292K Sell
3,320
-21,712
-87% -$1.81M ﹤0.01% 1451
2018
Q4 		$1.79M Buy
25,032
+13,732
+122% +$1.32M 0.02% 886
2018
Q3 		$1.39M Buy
+11,300
New +$1.28M 0.01% 1260
2017
Q2 		– Sell
-146,598
Closed -$6.35M – 1641
2017
Q1 		$6.35M Buy
146,598
+117,886
+411% +$5.05M 0.05% 392
2016
Q4 		$1.11M Buy
28,712
+15,760
+122% +$713K 0.01% 981
2016
Q3 		$656K Sell
12,952
-64,169
-83% -$3.2M 0.01% 1108
2016
Q2 		$3.5M Buy
77,121
+68,711
+817% +$3.16M 0.03% 542
2016
Q1 		$333K Sell
8,410
-84,126
-91% -$3.34M ﹤0.01% 1283
2015
Q4 		$5.24M Sell
92,536
-217,173
-70% -$11M 0.05% 435
2015
Q3 		$12.3M Buy
309,709
+238,342
+334% +$11.5M 0.14% 191
2015
Q2 		$3.41M Buy
+71,367
New +$3.03M 0.04% 472

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Capital Fund Management (CFM)'s NBIX Position: Q2 2026 in Review

Capital Fund Management (CFM) reduced its Neurocrine Biosciences (NBIX) stake by 34% in Q2 2026, selling an estimated $7.64M and leaving 98,117 shares worth $16.5M. The position accounts for 0.07% of the portfolio, ranked #389.

Capital Fund Management (CFM) first reported a position in NBIX in Q2 2015 and has held it in 26 quarters since. The position peaked at $25.6M in Q2 2025. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Capital Fund Management (CFM) held 98,117 shares of Neurocrine Biosciences worth $16.5M as of Q2 2026.
  • Capital Fund Management (CFM) sold 51,514 Neurocrine Biosciences shares in Q2 2026, an estimated $7.64M.
  • Neurocrine Biosciences made up 0.07% of Capital Fund Management (CFM)'s portfolio in Q2 2026, its #389 holding.
  • Capital Fund Management (CFM) first reported a position in Neurocrine Biosciences in Q2 2015 and has held it in 26 quarters since.
  • Capital Fund Management (CFM)'s Neurocrine Biosciences position peaked at $25.6M in Q2 2025.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2026, filed 13 Aug 2026.